A randomized, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Alzheimers disease
Latest Information Update: 08 Oct 2016
Price :
$35 *
At a glance
- Drugs Pleconaril (Primary) ; Ribavirin (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Apodemus
- 07 Oct 2016 Status changed from recruiting to completed.
- 25 Sep 2013 New trial record